Chong Kun Dang's 'ADC Candidate Substance' Selected for Support Project by National New Drug Development Program

Jongkundang recently announced on the 16th that its new drug candidate, 'CKD-ADC,' has been selected for the project 'Support for Excellent New Drug Development to Promote Global Expansion and Partnering,' promoted by the National New Drug Development Project Group. With this selection, Jongkundang will receive research support from the National New Drug Development Project Group for overseas non-clinical trials and clinical phase 1 approval to facilitate the global expansion of CKD-ADC.

Kwak Young-shin, Head of the CJ CheilJedang Hyojong Research Institute (left), and Park Young-min, Director of the National New Drug Development Project Group, are posing for a commemorative photo at the national new drug development project agreement ceremony.
[Photo by CJ CheilJedang]

CKD-ADC is a new drug candidate based on an antibody-drug conjugate (ADC) targeting solid tumors. It is described as a next-generation anticancer agent that combines Jongkundang’s independently developed c-MET antibody with Synaffix’s ADC technology, expected to have high selectivity for cancer cells. By conjugating cytotoxic drugs to antibodies, it aims to precisely target cancer cells while minimizing effects on normal cells, thereby achieving both efficacy and reduced side effects.

A representative from Jongkundang stated, “The selection for this new drug development support project is a recognition of the distinctiveness and innovation of the next-generation anticancer agent CKD-ADC. Based on government support, we will enhance research efficiency using optimized ADC platform technology and accelerate global market entry through the development of differentiated ADC anticancer drugs.”

This content was produced with the assistance of AI translation services.